Aptus Pharma Limited Seeks Shareholder Approval for Capital Increase and Bonus Shares
Aptus Pharma Limited has initiated a postal ballot to seek shareholder approval for increasing the company’s authorized share capital and issuing bonus shares. The move, announced on March 26, 2026, follows a board meeting on March 24, 2026.The company proposes to increase the authorized share capital from INR 71,50,00,000, comprising 71,50,000 equity shares of INR 10 each, to INR 25,00,00,000, divided into 2,50,00,000 equity shares of INR 10 each. Simultaneously, the company plans to issue bonus shares in a ratio of 3:2, equivalent to 3 bonus equity shares for every 2 existing shares held.
The voting period for the postal ballot will be as follows:
| Particulars | Dates and Time |
|---|---|
| Dispatch of Notice (electronic) | March 25, 2026 |
| Commencement of e-voting | Friday, March 27, 2026, 9:00 A.M. (IST) |
| End of e-voting | Saturday, April 25, 2026, 5:00 P.M. (IST) |
| Results Announcement | Within 2 working days from the voting period’s closure |
Shareholders can access the Postal Ballot Notice, Explanatory Statement, and remote e-voting instructions on the company website at www.aptuspharma.com, the CDSL e-voting website at www.evotingindia.com, and the website of the RTA, Accurate Securities And Registry Private Limited, at www.accuratesecurities.com/. The BSE Limited website (https://www.bseindia.com) will also host the information.
The resolutions require ordinary resolutions and are being pursued to facilitate future capital infusions and reward shareholder support. The Board of Directors has appointed M/s. Nalin Ganatra, Company Secretaries, as Scrutinizers to oversee the voting process. Results are expected to be declared within two working days of the voting period's conclusion.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.